Virus Targeting Recombinant Agent Platform
for Infectious Diseases
Targeting Unmet Needs for Patients with Viral Diseases
Significant unmet needs exist for patients suffering from viral diseases. A new disease of viral origin, Covid-19, has impacted patients on a global scale and there is a lack of therapeutic options. However, even patients suffering from many existing viral diseases (such as Human Immunodeficiency Virus, Hepatitis B Virus, Respiratory Syncytial Virus etc.) still do not have adequate therapeutic options. That is where PineTree Therapeutics comes in with its ViTRAP technology.
ViTRAP is a unique, broad spectrum, antiviral technology which can design discrete, disease-specific, biologic therapeutics for many diseases with unmet needs on a global basis.
Our areas of focus:
Moreover, ViTRAP therapeutics have demonstrated to be mutation/variant-agnostic, binding strongly to the four variants (US, UK, Brazilian and South African) of Covid-19.